Cargando…

696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies

BACKGROUND: Cefiderocol (S-649266, CFDC) is a novel siderophore cephalosporin with activity against a wide variety of Gram-negative bacteria including carbapenem-resistant strains. We previously reported that CFDC is efficiently transported into Pseudomonas aeruginosa via iron transporter PiuA. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Akinobu, Nishikawa, Toru, Ishii, Ryuta, Kuroiwa, Miho, Ishioka, Yoshino, Kurihara, Naoko, Sakikawa, Ikue, Ota, Takeshi, Rokushima, Masatomo, Tsuji, Masakatsu, Sato, Takafumi, Yamano, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254112/
http://dx.doi.org/10.1093/ofid/ofy210.703
_version_ 1783373649136320512
author Ito, Akinobu
Nishikawa, Toru
Ishii, Ryuta
Kuroiwa, Miho
Ishioka, Yoshino
Kurihara, Naoko
Sakikawa, Ikue
Ota, Takeshi
Rokushima, Masatomo
Tsuji, Masakatsu
Sato, Takafumi
Yamano, Yoshinori
author_facet Ito, Akinobu
Nishikawa, Toru
Ishii, Ryuta
Kuroiwa, Miho
Ishioka, Yoshino
Kurihara, Naoko
Sakikawa, Ikue
Ota, Takeshi
Rokushima, Masatomo
Tsuji, Masakatsu
Sato, Takafumi
Yamano, Yoshinori
author_sort Ito, Akinobu
collection PubMed
description BACKGROUND: Cefiderocol (S-649266, CFDC) is a novel siderophore cephalosporin with activity against a wide variety of Gram-negative bacteria including carbapenem-resistant strains. We previously reported that CFDC is efficiently transported into Pseudomonas aeruginosa via iron transporter PiuA. In this study, we examined frequency of resistance of P. aeruginosa to CFDC, and investigated the resistance mechanisms of appeared colonies. METHODS: Frequency of resistance (FoR) was determined by plating an overnight culture of P. aeruginosa PAO1 on Mueller–Hinton Agar containing 4× or 10×MIC of CFDC or ceftazidime (CAZ). Appeared colonies were analyzed by whole-genome sequencing (WGS) to identify genomic mutations. The mRNA expression was determined by real-time RT-PCR, and pyoverdine production was determined by MALDI-TOF/MS and expression of outer membrane protein was analyzed by SDS–PAGE and proteomic analysis. RESULTS: The FoR to CFDC was 2.9 × 10(–8) and <7.1 × 10(–8), which were lower than those to CAZ (3.1 × 10(–7) and 3.4 × 10(–8)) in the conditions of 4× and 10×MIC, respectively. MIC of CFDC against CFDC-derived mutant increased from 0.5 μg/mL (MIC against PAO1) to 2 μg/mL, and MICs of CAZ did not increase. In the case of CAZ-derived mutant, MICs of CAZ increased from 1 μg/mL (MIC against PAO1) to 16 μg/mL or higher, though MIC of CFDC did not increase, suggesting no cross-resistance between CFDC and CAZ. WGS identified mutations in upstream regions of pvdS (pvdS mutant), which regulates pyoverdine synthesis, or fecI (fecI mutant), which regulates the synthesis of iron transporter FecA contributing to the transport of iron citrate. The pvdS expression and pyoverdine production in the pvdS mutant were more than 4- and 6-fold higher than those in PAO1, respectively. The expression of fecA in the fecI mutant was more than ninefold higher than that in PAO1. CONCLUSION: The MIC increase of CFDC against P. aeruginosa occurred due to the mutation of iron transporter-related genes. The resistance acquisition risks should be low as the frequency of resistance to CFDC was lower and the MIC increase of CFDC against the mutants was smaller than that of CAZ. In addition, no cross-resistance between CFDC and CAZ was observed. DISCLOSURES: A. Ito, Shionogi & Co., Ltd.: Employee, Salary. T. Nishikawa, Shionogi & Co., Ltd.: Employee, Salary. R. Ishii, Shionogi & Co., Ltd.: Employee, Salary. M. Kuroiwa, Shionogi & Co., Ltd.: Employee, Salary. Y. Ishioka, Shionogi & Co., Ltd.: Employee, Salary. N. Kurihara, Shionogi & Co., Ltd.: Employee, Salary. I. Sakikawa, Shionogi & Co., Ltd.: Employee, Salary. T. Ota, Shionogi & Co., Ltd.: Employee, Salary. M. Rokushima, Shionogi & Co., Ltd.: Employee, Salary. M. Tsuji, SHIONOGI & CO., LTD.: Employee, Salary. T. Sato, SHIONOGI & CO., LTD.: Employee, Salary. Y. Yamano, SHIONOGI & CO., LTD.: Employee, Salary.
format Online
Article
Text
id pubmed-6254112
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62541122018-11-28 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies Ito, Akinobu Nishikawa, Toru Ishii, Ryuta Kuroiwa, Miho Ishioka, Yoshino Kurihara, Naoko Sakikawa, Ikue Ota, Takeshi Rokushima, Masatomo Tsuji, Masakatsu Sato, Takafumi Yamano, Yoshinori Open Forum Infect Dis Abstracts BACKGROUND: Cefiderocol (S-649266, CFDC) is a novel siderophore cephalosporin with activity against a wide variety of Gram-negative bacteria including carbapenem-resistant strains. We previously reported that CFDC is efficiently transported into Pseudomonas aeruginosa via iron transporter PiuA. In this study, we examined frequency of resistance of P. aeruginosa to CFDC, and investigated the resistance mechanisms of appeared colonies. METHODS: Frequency of resistance (FoR) was determined by plating an overnight culture of P. aeruginosa PAO1 on Mueller–Hinton Agar containing 4× or 10×MIC of CFDC or ceftazidime (CAZ). Appeared colonies were analyzed by whole-genome sequencing (WGS) to identify genomic mutations. The mRNA expression was determined by real-time RT-PCR, and pyoverdine production was determined by MALDI-TOF/MS and expression of outer membrane protein was analyzed by SDS–PAGE and proteomic analysis. RESULTS: The FoR to CFDC was 2.9 × 10(–8) and <7.1 × 10(–8), which were lower than those to CAZ (3.1 × 10(–7) and 3.4 × 10(–8)) in the conditions of 4× and 10×MIC, respectively. MIC of CFDC against CFDC-derived mutant increased from 0.5 μg/mL (MIC against PAO1) to 2 μg/mL, and MICs of CAZ did not increase. In the case of CAZ-derived mutant, MICs of CAZ increased from 1 μg/mL (MIC against PAO1) to 16 μg/mL or higher, though MIC of CFDC did not increase, suggesting no cross-resistance between CFDC and CAZ. WGS identified mutations in upstream regions of pvdS (pvdS mutant), which regulates pyoverdine synthesis, or fecI (fecI mutant), which regulates the synthesis of iron transporter FecA contributing to the transport of iron citrate. The pvdS expression and pyoverdine production in the pvdS mutant were more than 4- and 6-fold higher than those in PAO1, respectively. The expression of fecA in the fecI mutant was more than ninefold higher than that in PAO1. CONCLUSION: The MIC increase of CFDC against P. aeruginosa occurred due to the mutation of iron transporter-related genes. The resistance acquisition risks should be low as the frequency of resistance to CFDC was lower and the MIC increase of CFDC against the mutants was smaller than that of CAZ. In addition, no cross-resistance between CFDC and CAZ was observed. DISCLOSURES: A. Ito, Shionogi & Co., Ltd.: Employee, Salary. T. Nishikawa, Shionogi & Co., Ltd.: Employee, Salary. R. Ishii, Shionogi & Co., Ltd.: Employee, Salary. M. Kuroiwa, Shionogi & Co., Ltd.: Employee, Salary. Y. Ishioka, Shionogi & Co., Ltd.: Employee, Salary. N. Kurihara, Shionogi & Co., Ltd.: Employee, Salary. I. Sakikawa, Shionogi & Co., Ltd.: Employee, Salary. T. Ota, Shionogi & Co., Ltd.: Employee, Salary. M. Rokushima, Shionogi & Co., Ltd.: Employee, Salary. M. Tsuji, SHIONOGI & CO., LTD.: Employee, Salary. T. Sato, SHIONOGI & CO., LTD.: Employee, Salary. Y. Yamano, SHIONOGI & CO., LTD.: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6254112/ http://dx.doi.org/10.1093/ofid/ofy210.703 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ito, Akinobu
Nishikawa, Toru
Ishii, Ryuta
Kuroiwa, Miho
Ishioka, Yoshino
Kurihara, Naoko
Sakikawa, Ikue
Ota, Takeshi
Rokushima, Masatomo
Tsuji, Masakatsu
Sato, Takafumi
Yamano, Yoshinori
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
title 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
title_full 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
title_fullStr 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
title_full_unstemmed 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
title_short 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
title_sort 696. mechanism of cefiderocol high mic mutants obtained in non-clinical for studies
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254112/
http://dx.doi.org/10.1093/ofid/ofy210.703
work_keys_str_mv AT itoakinobu 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT nishikawatoru 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT ishiiryuta 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT kuroiwamiho 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT ishiokayoshino 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT kuriharanaoko 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT sakikawaikue 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT otatakeshi 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT rokushimamasatomo 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT tsujimasakatsu 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT satotakafumi 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies
AT yamanoyoshinori 696mechanismofcefiderocolhighmicmutantsobtainedinnonclinicalforstudies